Patient demographics and characteristics measured at baseline
| . | Patients developing HL (n = 78) . | Patients free of HL (n = 40 090) . |
|---|---|---|
| Median age, y (IQR) | 36.4 (33.1-41.3) | 36.1 (30.7-42.7) |
| Age, y, n (%) | ||
| 16-29 | 13 (17) | 8815 (22) |
| 30-39 | 41 (53) | 17 869 (45) |
| 40-49 | 12 (15) | 8668 (22) |
| At least 50 | 12 (15) | 4738 (12) |
| Sex, n (%) | ||
| Women | 19 (24) | 12 064 (30) |
| Men | 59 (76) | 28 026 (70) |
| Transmission risk group, n (%) | ||
| Injection-drug use | 17 (22) | 7642 (19) |
| MSM | 24 (31) | 10 592 (26) |
| Heterosexual | 22 (28) | 17 462 (44) |
| Other/unknown | 15 (19) | 4394 (11) |
| CDC clinical stage, n (%) | ||
| A/B | 64 (82) | 33 376 (83) |
| C | 14 (18) | 6714 (17) |
| Median CD4 cell count, cells/μL (IQR) | 170 (97-317) | 234 (96-400) |
| CD4 cell count, n (%) | ||
| < 50 cells/μL | 10 (13) | 5621 (14) |
| 50-99 cells/μL | 8 (10) | 3546 (9) |
| 100-199 cells/μL | 20 (26) | 6423 (16) |
| 200-349 cells/μL | 14 (18) | 8942 (22) |
| ≥ 350 cells/μL | 17 (22) | 11 247 (28) |
| Missing | 9 (12) | 4311 (11) |
| Median plasma HIV-1 RNA, copies/mL (IQR) | 100 340 (24 698-259 445) | 74 200 (18 437-227 000) |
| Plasma HIV-1 RNA, n (%) | ||
| ≥ 500 000 copies/mL | 9 (12) | 3956 (10) |
| 100 000-499 999 copies/mL | 22 (28) | 9371 (23) |
| 10 000-99 999 copies/mL | 21 (27) | 12 331 (31) |
| 501-9999 copies/mL | 8 (10) | 4992 (12) |
| ≤ 500 copies/mL | 0 (0) | 323 (1) |
| Missing | 18 (23) | 9117 (23) |
| . | Patients developing HL (n = 78) . | Patients free of HL (n = 40 090) . |
|---|---|---|
| Median age, y (IQR) | 36.4 (33.1-41.3) | 36.1 (30.7-42.7) |
| Age, y, n (%) | ||
| 16-29 | 13 (17) | 8815 (22) |
| 30-39 | 41 (53) | 17 869 (45) |
| 40-49 | 12 (15) | 8668 (22) |
| At least 50 | 12 (15) | 4738 (12) |
| Sex, n (%) | ||
| Women | 19 (24) | 12 064 (30) |
| Men | 59 (76) | 28 026 (70) |
| Transmission risk group, n (%) | ||
| Injection-drug use | 17 (22) | 7642 (19) |
| MSM | 24 (31) | 10 592 (26) |
| Heterosexual | 22 (28) | 17 462 (44) |
| Other/unknown | 15 (19) | 4394 (11) |
| CDC clinical stage, n (%) | ||
| A/B | 64 (82) | 33 376 (83) |
| C | 14 (18) | 6714 (17) |
| Median CD4 cell count, cells/μL (IQR) | 170 (97-317) | 234 (96-400) |
| CD4 cell count, n (%) | ||
| < 50 cells/μL | 10 (13) | 5621 (14) |
| 50-99 cells/μL | 8 (10) | 3546 (9) |
| 100-199 cells/μL | 20 (26) | 6423 (16) |
| 200-349 cells/μL | 14 (18) | 8942 (22) |
| ≥ 350 cells/μL | 17 (22) | 11 247 (28) |
| Missing | 9 (12) | 4311 (11) |
| Median plasma HIV-1 RNA, copies/mL (IQR) | 100 340 (24 698-259 445) | 74 200 (18 437-227 000) |
| Plasma HIV-1 RNA, n (%) | ||
| ≥ 500 000 copies/mL | 9 (12) | 3956 (10) |
| 100 000-499 999 copies/mL | 22 (28) | 9371 (23) |
| 10 000-99 999 copies/mL | 21 (27) | 12 331 (31) |
| 501-9999 copies/mL | 8 (10) | 4992 (12) |
| ≤ 500 copies/mL | 0 (0) | 323 (1) |
| Missing | 18 (23) | 9117 (23) |
MSM indicates men who have sex with men; and baseline, first visit after January 1, 1998.